Page last updated: 2024-09-04

kw 2189 and Blood Diseases

kw 2189 has been researched along with Blood Diseases in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Alberts, SR; Ames, MM; Erlichman, C; Goldberg, RM; Reid, JM; Richardson, RL; Sloan, JA	1

Trials

1 trial(s) available for kw 2189 and Blood Diseases

Article	Year
Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks. Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:9 Topics: Adult; Aged; Antibiotics, Antineoplastic; Drug Administration Schedule; Duocarmycins; Female; Hematologic Diseases; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasms; Pyrrolidinones	1998

Article

Year

Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks.

Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:9

Topics: Adult; Aged; Antibiotics, Antineoplastic; Drug Administration Schedule; Duocarmycins; Female; Hematologic Diseases; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasms; Pyrrolidinones

1998